Crown Castle (CCI)vsSanofi ADR (SNY)
CCI
Crown Castle
$94.49
+0.75%
REAL ESTATE · Cap: $40.22B
SNY
Sanofi ADR
$44.38
+4.74%
HEALTHCARE · Cap: $102.45B
Smart Verdict
WallStSmart Research — data-driven comparison
Sanofi ADR generates 1024% more annual revenue ($47.35B vs $4.21B). CCI leads profitability with a 25.1% profit margin vs 16.0%. CCI appears more attractively valued with a PEG of 1.50. SNY earns a higher WallStSmart Score of 51/100 (C-).
CCI
Hold49
out of 100
Grade: D+
SNY
Buy51
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-29.8%
Fair Value
$66.29
Current Price
$94.49
$28.20 premium
Margin of Safety
+5.6%
Fair Value
$49.84
Current Price
$44.38
$5.46 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Strong operational efficiency at 47.7%
Conservative balance sheet, low leverage
Keeps 25 of every $100 in revenue as profit
Reasonable price relative to book value
Large-cap with strong market position
Conservative balance sheet, low leverage
Strong operational efficiency at 20.0%
Generating 1.7B in free cash flow
Areas to Watch
Premium valuation, high expectations priced in
Weak financial health signals
ROE of -206.7% — below average capital efficiency
Revenue declined 4.8%
Expensive relative to growth rate
Earnings declined 11.7%
Comparative Analysis Report
WallStSmart ResearchBull Case : CCI
The strongest argument for CCI centers on Operating Margin, Debt/Equity, Profit Margin. Profitability is solid with margins at 25.1% and operating margin at 47.7%.
Bull Case : SNY
The strongest argument for SNY centers on Price/Book, Market Cap, Debt/Equity. Profitability is solid with margins at 16.0% and operating margin at 20.0%.
Bear Case : CCI
The primary concerns for CCI are P/E Ratio, Piotroski F-Score, Return on Equity.
Bear Case : SNY
The primary concerns for SNY are PEG Ratio, EPS Growth.
Key Dynamics to Monitor
CCI profiles as a declining stock while SNY is a mature play — different risk/reward profiles.
CCI carries more volatility with a beta of 0.95 — expect wider price swings.
SNY is growing revenue faster at 6.0% — sustainability is the question.
SNY generates stronger free cash flow (1.7B), providing more financial flexibility.
Bottom Line
SNY scores higher overall (51/100 vs 49/100), backed by strong 16.0% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Crown Castle
REAL ESTATE · REIT - SPECIALTY · USA
Crown Castle is a real estate investment trust and provider of shared communications infrastructure in the United States. Its network includes over 40,000 cell towers and nearly 80,000 route miles of fiber supporting small cells and fiber solutions. Headquartered in Houston, Texas, the company has 100 offices nationwide.
Visit Website →Sanofi ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Sanofi, a healthcare company, is engaged in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. The company is headquartered in Paris, France.
Compare with Other REIT - SPECIALTY Stocks
Want to dig deeper into these stocks?